CX-801 is under development for the treatment of metastatic solid tumors including metastatic melanoma, metastatic renal cell carcinoma (RCC) and head and neck squamous cell carcinoma (HNSCC). It is a ...
HB-0036 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback